Utah agreement permits Nolla AI acne prescriptions; pilot start unconfirmed

Utah signed an agreement on September 22 allowing Nolla Health to issue a narrow set of AI-initiated topical acne prescriptions to eligible adults. Yet the state’s authorized-pilots page says the demonstration period has not started, while Nolla’s service page says its Utah pilot is available. The agreement makes commencement depend on both customer availability and written notice to the state. The public record reviewed for this article does not resolve whether that notice was delivered.

The big change

• What changed: Utah’s agreement permits Nolla’s system to initiate certain topical acne prescriptions for adults, within a limited formulary and staged oversight plan.
• Why it matters: The agreement creates a route for AI to start some prescriptions without a physician initiating each one. Its safeguards and state reporting obligations make oversight part of the service’s operating terms.
• What to watch: The state says the demonstration period has not begun. The agreement’s start condition and any later phase changes make the state’s written record central to knowing what is operating and under which level of review.

What Utah authorized

The signed regulatory mitigation agreement, dated September 22, names Magic Health, Inc. and Magic Health Services, LLC, which do business as Nolla Health. It permits the companies’ AI technology to issue first-time prescriptions and refills for topical acne treatments to eligible Utah residents aged 18 or older, and transmit those orders to a Utah-licensed pharmacist. The agreement applies only to that defined activity; it does not cover Nolla’s other services.

The scope excludes oral acne drugs and isotretinoin. The attached pilot proposal limits patients to mild or moderate acne and lists additional exclusions, including pregnancy or plans to become pregnant, breastfeeding, known immunosuppression, severe kidney or liver disease, and a prior adverse reaction to a medication in the approved formulary. Identity, age and Utah residency checks are required. Pharmacists must be told when a prescription was generated by AI and receive contact information for Nolla’s licensed physicians.

Oversight is staged. In the first stage, two independent Utah-licensed physicians review each prescription before it is sent. The proposal describes later stages with retrospective physician review and, eventually, sampling-based review. The agreement says Nolla cannot move to a succeeding phase without the Office of Artificial Intelligence Policy’s prior written approval. The company must report adverse events within 24 hours after detection and submit monthly reports that include prescription counts, clinician agreement rates and escalations.

Those terms are a grant of limited regulatory mitigation. The agreement explicitly says it is not a state endorsement or approval of Nolla’s use of AI. The companies remain subject to other applicable laws and the agreement’s limits.

The start-date discrepancy

Section 2 defines the commencement date as the date Nolla makes the AI technology available to customers and delivers written notice to the Office that it is available. Both conditions appear in the definition. The state’s authorized-pilots listing identifies Nolla’s agreement as signed September 22, but says the demonstration period has not started. Nolla’s service page, by contrast, describes the pilot as available to Utah adults aged 18 and older.

The agreement was signed, but signature alone does not establish the commencement date under its own terms. The public materials reviewed here do not include a written commencement notice, and the state listing’s status conflicts with Nolla’s availability language. This reporting cannot determine whether notice was sent through another channel, whether anyone has received a prescription under the pilot, or whether the state page is out of date. The pilot’s commencement therefore remains unconfirmed.

Nolla’s page describes a scan and questionnaire followed by an AI-generated prescription, and advertises access “from $4.99/month.” Those are company statements about the service. They do not establish that a customer has received care under the Utah agreement, and the advertised subscription price is distinct from any medication charge. The signed terms and state listing offer a stronger basis for describing the authorized scope and formal status than product marketing does for proving operation.

How this differs from Utah’s Doctronic pilot

Utah’s listing also describes a separate Doctronic program for prescription renewals. That program concerns renewals of existing prescriptions on a fixed medication list; its current listing says it remains in its first phase, where a licensed practitioner authorizes each request. Nolla’s agreement instead covers first-time topical acne prescriptions as well as refills. Both are narrow regulatory arrangements, but they test different prescribing tasks.

The distinction matters because “AI prescribing” can refer to different levels of authority. Nolla’s agreement lays out a path from physician review of every prescription toward less frequent review, subject to explicit performance and state-approval gates. The central public question is whether and when the first stage began. Until the commencement condition is documented consistently, the agreement shows what Utah permits under stated safeguards, while the contradictory status statements leave the pilot’s operation unresolved.

Sources & further reading

• Utah’s signed regulatory mitigation agreement with Nolla Health, dated September 22, 2026. Section 2 defines the commencement date as customer availability plus written notice to the Office. Schedule A limits the regulatory mitigation to first-time and refill topical acne prescriptions for eligible Utah adults. Schedule B contains the pilot protocol, exclusions, staged physician oversight and reporting terms. The agreement says the mitigation is not state endorsement.
• Utah Office of Artificial Intelligence Policy’s authorized-pilots listing, checked October 6, 2026. It lists Nolla’s agreement as signed September 22 and says the demonstration period has not started. It also describes the separate Doctronic prescription-renewal pilot.
• Nolla Derm AI prescriptions, checked October 6, 2026. Nolla’s service page calls the Utah pilot available and describes its customer-facing scan, intake, physician access and advertised subscription price. These are company claims and do not resolve the agreement’s commencement condition.
• Nolla Health’s October 5 announcement. The company’s announcement presents the service as available; it does not independently establish whether the required written notice was delivered.
• STAT’s report on Utah’s health AI sandbox, October 5, 2026. Independent context on the state program and oversight; the signed agreement remains the primary source for Nolla’s permitted scope.